Sponsor content
270 result(s) found, displaying 61 to 70
-
Australian Public Assessment Report (AusPAR)AusPAR for Rybrevant (amivantamab) for treatment of patients with NSCLC that has an EGFR exon 20 insertion mutation.
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INVEGA HAFYERA paliperidone (as palmitate) 1000 mg in 5 mL modified release suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INVEGA HAFYERA paliperidone (as palmitate) 700 mg in 3.5 mL modified release suspension for injection pre-filled syringe.
-
Prescription medicine decision summaryThe medicine Tecvayli (teclistamab) has been approved by the TGA to treat multiple myeloma.
-
Prescription medicine registrationActive ingredients: T cells - Ciltacabtagene autoleucel, cryopreserved - T - CARVYKTI .
-
Prescription medicine registrationActive ingredients: teclistamab.
-
-
Prescription medicine decision summaryTGA decision: Rybrevant (amivantamab) is approved to treat lung cancer
-
Designation or determinationProvisional determination